Buscar
08/02/2022
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1
Onate, G, Bataller, A, Garrido, A, Hoyos, M, Arnan, M, Vives, S, Coll, R, Tormo, M, Sampol, A, Escoda, L, Salamero, O, Garcia, A, Bargay, J, Aljarilla, A, Nomdedeu, JF, Esteve, J, Sierra, J, Pratcorona, M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2020004136. PMID:34516636. IF:7.500(Q1/2D).
08/02/2022
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani, K, Gomez-Arteaga, A, Madero-Marroquin, R, Zhang, MJ, Bo-Subait, K, Sanchez, J, Wang, HL, Aljurf, M, Assal, A, Bacher, VU, Badawy, SM, Bejanyan, N, Bhatt, VR, Bredeson, C, Byrne, M, Castillo, P, Cerny, J, Chhabra, S, Ciurea, SO, DeFilipp, Z, Farhadfar, N, Gadalla, S, Gale, RP, Ganguly, S, Gowda, L, Grunwald, MR, Hashmi, S, Hildebrandt, G, Kanakry, CG, Kansagra, A, Khimani, F, Krem, M, Lazarus, H, Liu, HT, Martino, R, Michelis, FV, Nathan, S, Nishihori, T, Olsson, R, Reshef, R, Rizzieri, D, Rowe, JM, Savani, BN, Seo, S, Sharma, A, Solh, M, Ustun, C, Verdonck, LF, Hourigan, C, Sandmaier, B, Litzow, M, Kebriaei, P, Weisdorf, D, Zhang, YM, Tallman, MS, Saber, W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7.500(Q1/2D).
04/02/2022
CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma
Rioja-Blanco, E, Arroyo-Solera, I, Alamo, P, Casanova, I, Gallardo, A, Unzueta, U, Serna, N, Sanchez-Garcia, L, Quer, M, Villaverde, A, Vazquez, E, Leon, X, Alba-Castellon, L, Mangues, R. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2022; 41(1)DOI:10.1186/s13046-022-02267-8. PMID:35120582. IF:11.300(Q1/1D).
01/02/2022
Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome
Cortes-Vicente, E, Alvarez-Velasco, R, Pla-Junca, F, Rojas-Garcia, R, Paradas, C, Sevilla, T, Casasnovas, C, Gomez-Caravaca, MT, Pardo, J, Ramos-Fransi, A, Pelayo-Negro, AL, Gutierrez-Gutierrez, G, Turon-Sans, J, de Munain, AL, Guerrero-Sola, A, Jerico, I, Martin, MA, Mendoza, MD, Moris, G, Velez-Gomez, B, Garcia-Sobrino, T, Pascual-Goni, E, Reyes-Leiva, D, Illa, I, Gallardo, E. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals of Clinical and Translational Neurology. 2022; 9(2)DOI:10.1002/acn3.51492. PMID:35080153. IF:5.300(Q1/2D).